Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Universe Pharmaceuticals ...

    NASDAQ: UPC · Real-Time Price · USD
    3.71
    -0.08 (-2.11%)
    At close: Jun 27, 2025, 3:59 PM
    3.77
    1.52%
    After-hours: Jun 27, 2025, 05:58 PM EDT

    Universe Pharmaceuticals Statistics

    Share Statistics

    Universe Pharmaceuticals has 563.34K shares outstanding. The number of shares has increased by -0.24% in one year.

    Shares Outstanding

    n/a
    		 563.34K

    Shares Change (YoY)

    n/a
    		 -0.24%

    Shares Change (QoQ)

    n/a
    		 -0.05%

    Owned by Institutions (%)

    n/a
    		 0.47%

    Shares Floating

    n/a
    		 552.61K

    Failed to Deliver (FTD) Shares

    n/a
    		 14,061

    FTD / Avg. Volume

    n/a
    		 4.03%

    Short Selling Information

    The latest short interest is 41.17K, so 0.27% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 41.17K

    Short % of Shares Out

    n/a
    		 0.27%

    Short % of Float

    n/a
    		 0.27%

    Short Ratio (days to cover)

    n/a
    		 1

    Valuation Ratios

    The PE ratio is -10.19 and the forward PE ratio is null. Universe Pharmaceuticals's PEG ratio is -0.25.

    PE Ratio

    n/a
    		 -10.19

    Forward PE

    n/a
    		 n/a

    PS Ratio

    n/a
    		 3.86

    Forward PS

    n/a
    		 n/a

    PB Ratio

    n/a
    		 1.96

    P/FCF Ratio

    n/a
    		 -9.01

    PEG Ratio

    n/a
    		 -0.25
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Universe Pharmaceuticals.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 2.54, with a Debt / Equity ratio of 0.18.

    Current Ratio

    n/a
    		 2.54

    Quick Ratio

    n/a
    		 2.46

    Debt / Equity

    n/a
    		 0.18

    Debt / EBITDA

    n/a
    		 -1.09

    Debt / FCF

    n/a
    		 -0.81

    Interest Coverage

    n/a
    		 -28.83

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $102,330.92

    Profits Per Employee

    n/a
    		 $-38,787.99

    Employee Count

    n/a
    		 225

    Asset Turnover

    n/a
    		 0.34

    Inventory Turnover

    n/a
    		 9.76

    Taxes

    Income Tax

    n/a
    		 606.7K

    Effective Tax Rate

    n/a
    		 -7.47%

    Stock Price Statistics

    The stock price has increased by -99.75% in the last 52 weeks. The beta is 1.51, so Universe Pharmaceuticals's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.51

    52-Week Price Change

    n/a
    		 -99.75%

    50-Day Moving Average

    n/a
    		 4.48

    200-Day Moving Average

    n/a
    		 85.52

    Relative Strength Index (RSI)

    n/a
    		 41.08

    Average Volume (20 Days)

    n/a
    		 349,280

    Income Statement

    In the last 12 months, Universe Pharmaceuticals had revenue of 23.02M and earned -8.73M in profits. Earnings per share was -2.39.

    Revenue

    n/a
    		 23.02M

    Gross Profit

    n/a
    		 6.07M

    Operating Income

    n/a
    		 -8.02M

    Net Income

    n/a
    		 -8.73M

    EBITDA

    n/a
    		 -7.36M

    EBIT

    n/a
    		 -7.84M

    Earnings Per Share (EPS)

    n/a
    		 -2.39
    Full Income Statement

    Balance Sheet

    The company has 29.5M in cash and 7.99M in debt, giving a net cash position of 21.5M.

    Cash & Cash Equivalents

    n/a
    		 29.5M

    Total Debt

    n/a
    		 7.99M

    Net Cash

    n/a
    		 21.5M

    Retained Earnings

    n/a
    		 -10.17M

    Total Assets

    n/a
    		 67.95M

    Working Capital

    n/a
    		 31.32M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -9.51M and capital expenditures -363.09K, giving a free cash flow of -9.87M.

    Operating Cash Flow

    n/a
    		 -9.51M

    Capital Expenditures

    n/a
    		 -363.09K

    Free Cash Flow

    n/a
    		 -9.87M

    FCF Per Share

    n/a
    		 -16.24
    Full Cash Flow Statement

    Margins

    Gross margin is 26.37%, with operating and profit margins of -34.83% and -37.9%.

    Gross Margin

    n/a
    		 26.37%

    Operating Margin

    n/a
    		 -34.83%

    Pretax Margin

    n/a
    		 -35.27%

    Profit Margin

    n/a
    		 -37.9%

    EBITDA Margin

    n/a
    		 -31.95%

    EBIT Margin

    n/a
    		 -34.83%

    FCF Margin

    n/a
    		 -42.87%

    Dividends & Yields

    UPC does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    Currently there are no analyst rating for UPC.

    Price Target

    n/a
    		 n/a

    Price Target Difference

    n/a
    		 n/a

    Analyst Consensus

    n/a
    		 n/a

    Analyst Count

    n/a
    		 n/a
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Mar 24, 2025. It was a backward split with a ratio of 1:40.

    Last Split Date

    n/a
    		 Mar 24, 2025

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:40

    Scores

    Altman Z-Score

    n/a
    		 0.65

    Piotroski F-Score

    n/a
    		 1

    Add to Watchlist